Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: SHP2 inhibitor PHPS1 ameliorates acute kidney injury by Erk1/2-STAT3 signaling in a combined murine hemorrhage followed by septic challenge model

Fig. 1

SHP2 activation in the kidney is reduced by PHPS1 treatment. Diagram of experimental timeline for PHPS1 (3 mg/kg BW) administration, Hem, CLP and mice sacrifice (a). Twenty four h post-Hem/CLP or Sham operation, the kidneys were collected and tissue homogenates were obtained. The extent of SHP2 activation (phosphorylation) was determined by western blot (b, c). The ratio of phosphorylated SHP2 and total SHP2 (p-SHP2/t-SHP2) in kidneys from Hem/CLP mice was significantly increased compared to Shams. PHPS1 treated Hem/CLP mice showed reduced SHP2 activation compared to Veh treated Hem/CLP mice. *, P < 0.05, versus Sham (S/S); #, P < 0.05, PHPS1 treated group (Hem/CLP + PHPS1) versus Hem/CLP + vehicle (Hem/CLP). One-way ANOVA and a Student-Newman-Keuls’ test, Mean ± SD; n = 6 mice/group

Back to article page

Molecular Medicine

ISSN: 1528-3658